BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ll Wilkinson MG, Deakin CT, Papadopoulou C, Eleftheriou D, Wedderburn LR. JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology. Pediatr Rheumatol Online J 2021;19:146. [PMID: 34563217 DOI: 10.1186/s12969-021-00637-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Hinze C, Dressler F, Schara-schmidt U, Haas J. Juvenile Dermatomyositis. Aktuelle Rheumatologie 2022;47:99-109. [DOI: 10.1055/a-1769-4299] [Reference Citation Analysis]
2 Toplak N, Pimpale Chavan P, Rosina S, Dallos T, Rotem Semo O, Aguiar CL, Khubchandani R, Ravelli A, Patwardhan A. Is Anti-NXP2 Autoantibody a Risk Factor for Calcinosis and Poor Outcome in Juvenile Dermatomyositis Patients? Case Series. Front Pediatr 2022;9:810785. [DOI: 10.3389/fped.2021.810785] [Reference Citation Analysis]